Elebrato Ellipta

Țară: Uniunea Europeană

Limbă: engleză

Sursă: EMA (European Medicines Agency)

Ingredient activ:

fluticasone furoate, umeclidinium bromide, vilanterol trifenatate

Disponibil de la:

GlaxoSmithKline Trading Services Limited

Codul ATC:

R03AL08

INN (nume internaţional):

fluticasone furoate, umeclidinium, vilanterol

Grupul Terapeutică:

Drugs for obstructive airway diseases,

Zonă Terapeutică:

Pulmonary Disease, Chronic Obstructive

Indicații terapeutice:

Elebrato Ellipta is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting β2-agonist.

Rezumat produs:

Revision: 12

Statutul autorizaţiei:

Authorised

Data de autorizare:

2017-11-15

Prospect

31
B. PACKAGE LEAFLET
32
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT
ELEBRATO ELLIPTA 92 MICROGRAMS/55 MICROGRAMS/22 MICROGRAMS INHALATION
POWDER, PRE-DISPENSED
fluticasone furoate/umeclidinium/vilanterol
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS
MEDICINE BECAUSE IT CONTAINS IMPORTANT
INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor, pharmacist or
nurse.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them, even if
their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor, pharmacist or nurse.
This includes any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Elebrato Ellipta is and what it is used for
2.
What you need to know before you use Elebrato Ellipta
3.
How to use Elebrato Ellipta
4.
Possible side effects
5.
How to store Elebrato Ellipta
6.
Contents of the pack and other information
Step-by-step instructions
1.
WHAT ELEBRATO ELLIPTA IS AND WHAT IT IS USED FOR
WHAT ELEBRATO ELLIPTA IS
Elebrato Ellipta contains three active substances called fluticasone
furoate, umeclidinium bromide and
vilanterol. Fluticasone furoate belongs to a group of medicines called
corticosteroids, often simply called
steroids. Umeclidinium bromide and vilanterol belong to a group of
medicines called bronchodilators.
WHAT ELEBRATO ELLIPTA IS USED FOR
Elebrato Ellipta is used to treat chronic obstructive pulmonary
disease
_ _
(
COPD
) in adults. COPD is a long-
term condition characterised by breathing difficulties that slowly get
worse.
In COPD the muscles around the airways tighten, making breathing
difficult. This medicine widens these
muscles in the lungs, reducing the swelling and irritation in the
small air passages and making it easier for air
to get in and out of the lungs. When used regularly, it can help to
control your breathing difficulties and
reduce the effects of COPD on your everyday life.
ELE

Caracteristicilor produsului

1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Elebrato Ellipta 92 micrograms/55 micrograms/22 micrograms inhalation
powder, pre-dispensed
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each single inhalation provides a delivered dose (the dose leaving the
mouthpiece) of 92 micrograms
fluticasone furoate, 65 micrograms umeclidinium bromide equivalent to
55 micrograms umeclidinium and
22 micrograms vilanterol (as trifenatate). This corresponds to a
pre-dispensed dose of 100 micrograms
fluticasone furoate, 74.2 micrograms umeclidinium bromide equivalent
to 62.5 micrograms umeclidinium
and 25 micrograms vilanterol (as trifenatate).
Excipient with known effect
Each delivered dose contains approximately 25 mg of lactose
monohydrate.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Inhalation powder, pre-dispensed (inhalation powder)
White powder in a light grey inhaler (Ellipta) with a beige mouthpiece
cover and a dose counter.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Elebrato Ellipta is indicated as a maintenance treatment in adult
patients with moderate to severe chronic
obstructive pulmonary disease (COPD) who are not adequately treated by
a combination of an inhaled
corticosteroid and a long-acting β2-agonist or a combination of a
long-acting β2-agonist and a long-acting
muscarinic antagonist (for effects on symptom control and prevention
of exacerbations see section 5.1).
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
_ _
Posology
The recommended and maximum dose is one inhalation once daily, each
day at the same time.
If a dose is missed the next dose should be inhaled at the usual time
the next day.
_Special populations _
_Elderly_
No dose adjustment is required in patients 65 years of age or older
(see section 5.2).
_Renal impairment _
No dose adjustment is required in patients with renal impairment (see
section 5.2).
_Hepatic impairment _
3
No dose adjustment is required in patients with mild, moderate or
severe hepatic impairment. Elebrato
Ellipta